Dechra Pharmaceuticals
 |
|
| Type | Public (LSE: DPH) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Stoke-on-Trent, England |
| Key people | Michael Redmond, (Chairman) Ian Page, (CEO) |
| Products | Felimazola, Vetoryl |
| Services | National Veterinary Services, NationWide Laboratories |
| Revenue | £350.0 million (2009)[1] |
| Operating income | £25.0 million (2009)[1] |
| Net income | £11.3 million (2009)[1] |
| Employees | 1,012 (2009) |
| Website | www.dechra.com |
Dechra Pharmaceuticals plc (LSE: DPH) is a British-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a former constituent of the FTSE 250 Index.
Contents |
[edit] History
The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2]
In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3]
[edit] Operations
The Company has two divisions:[4]
- Pharmaceuticals - mainly for dogs, cats and horses; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats
- Services - National Veterinary Services - supply and distribution of veterinary products to veterinary practices; NationWide Laboratories - veterinary laboratory services
[edit] See also
[edit] References
|
||||||||||||||||||||
